BR112014017968A8 - Compostos de beta-lactama substituídos por amidina, sua preparação e uso como agentes antibacterianos - Google Patents

Compostos de beta-lactama substituídos por amidina, sua preparação e uso como agentes antibacterianos

Info

Publication number
BR112014017968A8
BR112014017968A8 BR112014017968A BR112014017968A BR112014017968A8 BR 112014017968 A8 BR112014017968 A8 BR 112014017968A8 BR 112014017968 A BR112014017968 A BR 112014017968A BR 112014017968 A BR112014017968 A BR 112014017968A BR 112014017968 A8 BR112014017968 A8 BR 112014017968A8
Authority
BR
Brazil
Prior art keywords
preparation
lactam compounds
antibacterial agents
substituted beta
amidine
Prior art date
Application number
BR112014017968A
Other languages
English (en)
Other versions
BR112014017968A2 (pt
Inventor
Schiffer Guido
Klenke Burkhard
Wiegand Irith
Broetz-Oester-Helt Heike
N Maiti Samarendra
Khan Jehangir
Reddy Andhe
Yang Zhixiang
Hena Mostafa
Jia Guofeng
Ligong Ou
Liang Hong
Yip Judy
Gao Chuanjun
Tajammul Sabiha
Mohammad Rahim
Biswajeet Ganguli
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of BR112014017968A2 publication Critical patent/BR112014017968A2/pt
Publication of BR112014017968A8 publication Critical patent/BR112014017968A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSTOS DE BETA-LACTAMA SUBSTITUÍDOS POR AMIDINA, SUA PREPARAÇÃO E USO COMO AGENTES ANTIBACTERIANOS. A presente invenção refere-se a novos compostos de ß-lactama de fórmula (I), a sua preparação e ao uso. Em particular, esta invenção refere-se a novos compostos de (beta)-lactama que são derivados de monobactam substituídos por amidina úteis como agentes antimicrobianos e sua preparação.
BR112014017968A 2012-01-24 2013-01-23 Compostos de beta-lactama substituídos por amidina, sua preparação e uso como agentes antibacterianos BR112014017968A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12152279 2012-01-24
PCT/EP2013/051217 WO2013110643A1 (en) 2012-01-24 2013-01-23 Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents

Publications (2)

Publication Number Publication Date
BR112014017968A2 BR112014017968A2 (pt) 2017-06-20
BR112014017968A8 true BR112014017968A8 (pt) 2017-07-11

Family

ID=47603723

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014017968A BR112014017968A8 (pt) 2012-01-24 2013-01-23 Compostos de beta-lactama substituídos por amidina, sua preparação e uso como agentes antibacterianos

Country Status (43)

Country Link
US (2) US9556165B2 (pt)
EP (1) EP2806873B1 (pt)
JP (1) JP5869701B2 (pt)
KR (1) KR102036393B1 (pt)
CN (1) CN104203237A (pt)
AP (1) AP2014007880A0 (pt)
AR (1) AR089796A1 (pt)
AU (1) AU2013211575B2 (pt)
BR (1) BR112014017968A8 (pt)
CA (1) CA2862338C (pt)
CL (1) CL2014001956A1 (pt)
CO (1) CO7101240A2 (pt)
CU (1) CU24273B1 (pt)
CY (1) CY1117955T1 (pt)
DK (1) DK2806873T3 (pt)
EA (1) EA027126B1 (pt)
EC (1) ECSP14010249A (pt)
ES (1) ES2592403T3 (pt)
HK (1) HK1203389A1 (pt)
HR (1) HRP20161171T1 (pt)
HU (1) HUE030452T2 (pt)
IL (1) IL233805A (pt)
IN (1) IN2014MN01640A (pt)
LT (1) LT2806873T (pt)
MA (1) MA35905B1 (pt)
ME (1) ME02532B (pt)
MX (1) MX346602B (pt)
MY (1) MY173843A (pt)
NZ (1) NZ626951A (pt)
PE (1) PE20142345A1 (pt)
PH (1) PH12014501671B1 (pt)
PL (1) PL2806873T3 (pt)
PT (1) PT2806873T (pt)
RS (1) RS55210B1 (pt)
SG (1) SG11201403930XA (pt)
SI (1) SI2806873T1 (pt)
SM (1) SMT201600354B (pt)
TN (1) TN2014000297A1 (pt)
TW (1) TWI659953B (pt)
UA (1) UA110880C2 (pt)
UY (1) UY34585A (pt)
WO (1) WO2013110643A1 (pt)
ZA (1) ZA201405057B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015103583A1 (en) * 2014-01-06 2015-07-09 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use
ES2719136T3 (es) 2014-03-24 2019-07-08 Novartis Ag Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas
CN105175335B (zh) * 2015-08-13 2017-11-03 南阳师范学院 一种3‑(3,3‑二氯烯丙氧基)‑1‑甲基吡唑‑5‑甲酰胺衍生物及其制备方法
KR20180054816A (ko) 2015-09-23 2018-05-24 노파르티스 아게 모노박탐 항생제의 염 및 고체 형태
JP7184646B2 (ja) 2015-12-15 2022-12-06 メルク・シャープ・アンド・ドーム・エルエルシー ビアリールモノバクタム化合物および細菌感染治療のためのそれの使用方法
MA43811A (fr) * 2016-03-07 2018-11-28 Merck Sharp & Dohme Composés d'arylmonobactame bicycliques et leurs méthodes d'utilisation pour le traitement des infections bactériennes
CN107641119B (zh) 2016-07-21 2019-11-08 中国科学院上海药物研究所 单环β-内酰胺-铁载体轭合物及其制备方法和用途
WO2018038906A1 (en) * 2016-08-26 2018-03-01 Codexis, Inc. Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
CA3043976A1 (en) 2016-11-18 2018-05-24 Aicuris Anti-Infective Cures Gmbh Liposomal formulations of amidine substituted beta-lactam compounds for use in the treatment of bacterial infections
CN110022857A (zh) 2016-11-18 2019-07-16 艾库里斯抗感染治疗有限公司 基于改性环糊精和酸化剂的脒取代β-内酰胺化合物的新制剂、其制备及作为抗微生物药物组合物的用途
MA47110A (fr) * 2016-12-21 2019-10-30 Aicuris Gmbh & Co Kg Polythérapie avec des composés de ss-lactame substitués par amidine et des inhibiteurs de ss-lactamase pour des infections par des souches bactériennes résistantes aux antibiotiques
CA3070010A1 (en) 2017-07-18 2019-01-24 Bayer Cropscience Aktiengesellschaft Substituted 3-heteroaryloxy-1h-pyrazoles and salts thereof and their use as herbicidal active substances
AR112464A1 (es) 2017-07-28 2019-10-30 Aicuris Anti Infective Cures Gmbh Forma cristalina de ácido (2s)-2-[[(z)-[1-(2-amino-4-tiazolil)-2-[[(3s)-2,2-dimetil-4-oxo-1-(sulfoxi)-3-azetidinil]amino]-2-oxoetiliden]amino]oxi]-3-[4-[imino[(3r)-3-piperidinilamino]metil]fenoxi]-propanoico
WO2019026004A2 (en) 2017-08-02 2019-02-07 Novartis Ag CHEMICAL PROCESS FOR THE PREPARATION OF ANTIBIOTIC MONOBACTAM AND ITS INTERMEDIATES
EP3691639B1 (en) * 2017-10-02 2023-11-15 Merck Sharp & Dohme LLC Chromane monobactam compounds for the treatment of bacterial infections
BR112020006594A2 (pt) * 2017-10-02 2020-12-15 Arixa Pharmaceuticals, Inc. Derivados de aztreonam e usos dos mesmos
WO2019144969A1 (zh) 2018-01-29 2019-08-01 南京明德新药研发股份有限公司 用于治疗细菌感染的单环β-内酰胺化合物
TW202024068A (zh) * 2018-11-13 2020-07-01 大陸商南京聖和藥業股份有限公司 單環內醯胺化合物及其應用
US20220062244A1 (en) 2018-12-18 2022-03-03 Medshine Discovery Inc. APPLICATION OF MONOCYCLIC ß-LACTAM COMPOUND IN PHARMACY
CN111303144B (zh) * 2019-12-13 2020-11-27 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
EP4079305A4 (en) 2019-12-19 2024-01-10 Shenzhen Optimum Biological Technology Co., Ltd APPLICATION OF A COMPOUND IN THE PREPARATION OF DRUG
CN111253405B (zh) * 2020-03-20 2022-12-16 南京安伦化工科技有限公司 一种比阿培南中间体的制备方法
CN111592536B (zh) * 2020-06-04 2023-11-03 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺化合物及其制备方法和应用
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
WO2022011626A1 (en) * 2020-07-16 2022-01-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel monobactam compounds, their preparation and use as antibacterial agents
EP4007759A4 (en) * 2020-08-06 2024-04-10 Ningxia Academy of Agriculture and Forestry Sciences BETA-LACTAM COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIAL AGENTS
CN112079791A (zh) * 2020-08-21 2020-12-15 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用
CN111909067B (zh) * 2020-08-28 2022-03-15 浙江凯普化工有限公司 一种d-青霉胺的有机全合成方法
AU2021473165A1 (en) * 2021-11-09 2024-05-23 Guangzhou HC New Drug Research Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING β-LACTAM COMPOUND AND USE THEREOF
WO2023091438A1 (en) 2021-11-18 2023-05-25 Merck Sharp & Dohme Llc Chromane amidine monobactam antibiotics

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794886A (fr) * 1972-02-22 1973-08-02 Pfizer Acides 6-(alpha-(omega-guanidinoalcanoylamino)acylamino)-penicillaniques
DE2458973A1 (de) * 1974-12-13 1976-06-16 Hoechst Ag Acylaminopenicillansaeuren und verfahren zu ihrer herstellung
DE2749265A1 (de) 1977-11-03 1979-05-10 Linde Ag Verfahren zur biologischen reinigung von abwasser
ZA806977B (en) * 1979-11-19 1981-10-28 Fujisawa Pharmaceutical Co 7-acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
JPS58210061A (ja) * 1982-05-31 1983-12-07 Takeda Chem Ind Ltd １−スルホ−２−オキソアゼチジン誘導体、その製造法および用途
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
NZ205642A (en) 1982-10-06 1986-08-08 Squibb & Sons Inc Beta-lactams and pharmaceutical compositions
US4638060A (en) 1985-04-29 1987-01-20 E. R. Squibb & Sons, Inc. O-sulfated spiro β-lactam hydroxamic acids
EP0336667A3 (en) 1988-04-04 1991-04-10 E.R. Squibb & Sons, Inc. [3S(Z)]-3-[[(2-amino-4-thiazolyl)[[2-(hydroxyamino)-2-oxoethoxy]imino]acetyl]-amino]-2,2-dimethyl-4-oxo-1-azetidinyl sulfate
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
CA2024282A1 (en) 1989-09-21 1991-03-22 Peter H. Ermann Heterocyclic hydrazide derivatives of monocyclic beta-lactam antibiotics
ZA918014B (en) 1990-11-05 1992-07-29 Squibb & Sons Inc Heteroaroyl derivatives of monocyclic beta-lactam antibiotics
US5250691A (en) 1991-09-09 1993-10-05 E. R. Squibb & Sons, Inc. Heteroaryl derivatives of monocyclic beta-lactam antibiotics
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
CN1189469C (zh) 2000-09-14 2005-02-16 潘斯瑞克有限公司 作为抗菌剂的3－(杂芳基乙酰氨基)－2－氧化－氮杂环丁烷－1－磺酸衍生物
CN1914151A (zh) 2004-01-27 2007-02-14 默克弗罗斯特公司 作为环氧合酶－2抑制剂的二芳基－2(5h)－呋喃酮类的释放一氧化氮的前药
PL1978959T3 (pl) 2005-09-23 2012-04-30 Ms Science Corp Pochodne piperydyny i piperazyny
PL1965798T3 (pl) 2005-12-07 2012-02-29 Basilea Pharmaceutica Ag Użyteczne antybiotyki monobaktamowe
EP1990336B1 (en) 2006-02-14 2012-02-08 Ihara Chemical Industry Co., Ltd. Process for production of 5-alkoxy-4-hydroxymethylpyrazole compound
US20090012054A1 (en) 2006-03-16 2009-01-08 Astellas Pharma Inc. Cephem Compounds and Use as Antimicrobial Agents
NZ579375A (en) * 2007-03-23 2012-02-24 Basilea Pharmaceutica Ag Combination medicaments for treating bacterial infections
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
EP2379546A1 (en) 2008-12-19 2011-10-26 Pfizer Inc. Monocarbams

Also Published As

Publication number Publication date
JP5869701B2 (ja) 2016-02-24
MA35905B1 (fr) 2014-12-01
CY1117955T1 (el) 2017-05-17
US9782390B2 (en) 2017-10-10
MX346602B (es) 2017-03-24
HRP20161171T1 (hr) 2016-11-04
EP2806873A1 (en) 2014-12-03
US20170100379A1 (en) 2017-04-13
EP2806873B1 (en) 2016-06-15
IL233805A (en) 2016-06-30
RS55210B1 (sr) 2017-01-31
PT2806873T (pt) 2016-09-23
US9556165B2 (en) 2017-01-31
KR102036393B1 (ko) 2019-10-24
AU2013211575B2 (en) 2017-03-02
AP2014007880A0 (en) 2014-08-31
SMT201600354B (it) 2016-11-10
ECSP14010249A (es) 2015-12-31
PH12014501671A1 (en) 2014-11-10
AR089796A1 (es) 2014-09-17
CA2862338A1 (en) 2013-08-01
ES2592403T3 (es) 2016-11-30
CA2862338C (en) 2019-04-16
IN2014MN01640A (pt) 2015-05-22
BR112014017968A2 (pt) 2017-06-20
NZ626951A (en) 2016-03-31
IL233805A0 (en) 2014-09-30
PH12014501671B1 (en) 2014-11-10
CU20140090A7 (es) 2014-12-26
MX2014008915A (es) 2014-08-26
HK1203389A1 (zh) 2015-10-30
KR20140114390A (ko) 2014-09-26
SG11201403930XA (en) 2014-08-28
CL2014001956A1 (es) 2014-11-07
ZA201405057B (en) 2017-09-27
MY173843A (en) 2020-02-24
TW201343643A (zh) 2013-11-01
EA027126B1 (ru) 2017-06-30
TN2014000297A1 (en) 2015-12-21
WO2013110643A1 (en) 2013-08-01
US20150045340A1 (en) 2015-02-12
LT2806873T (lt) 2016-10-10
CU24273B1 (es) 2017-08-08
CN104203237A (zh) 2014-12-10
TWI659953B (zh) 2019-05-21
UA110880C2 (uk) 2016-02-25
EA201400838A1 (ru) 2014-12-30
PL2806873T3 (pl) 2016-12-30
AU2013211575A1 (en) 2014-07-24
ME02532B (me) 2017-02-20
SI2806873T1 (sl) 2016-10-28
PE20142345A1 (es) 2015-01-09
UY34585A (es) 2013-09-02
DK2806873T3 (en) 2016-08-29
HUE030452T2 (en) 2017-05-29
CO7101240A2 (es) 2014-10-31
JP2015504907A (ja) 2015-02-16

Similar Documents

Publication Publication Date Title
BR112014017968A8 (pt) Compostos de beta-lactama substituídos por amidina, sua preparação e uso como agentes antibacterianos
BRPI0907435A8 (pt) derivados de 5-flúor pirimidina
BR112012027439A2 (pt) derivados de n1-sulfonil-5-flúor-pirimidinona n3-substituídos
BR112014029115A2 (pt) composto, composição farmacêutica, e, uso de um composto ou composição
UY33541A (es) N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas
BR112014003216A2 (pt) compostos, processos para preparação de compostos de fórmula i, composições agroquímicas, uso de compostos de fórmula i ou viii e uso de pelo menos um composto de fórmula i ou viii
BR112014014769A2 (pt) Composto, composição farmacêutica, e, uso de um composto ou sal.
BR112014029530A2 (pt) compostos, composição farmacêutica e uso de um composto
BR112014003587A2 (pt) derivados de 5-flúor-4-imino-3-(substituído)-3,4-di-hidropirimidin-2(1h)ona
UY33936A (es) Derivados de fluoro-piridinona útiles como agentesantibacterianos.
BR112014004310A2 (pt) composto de pirimidina inibidor da enzima fosfodiesterase 10, composição farmacêutica, uso de um composto
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
BR112015012825A2 (pt) piridopirazinas substituídas como inibidores de syk
BR112015006868A2 (pt) composições antibióticas de tazobactam arginina
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
IN2014MN02484A (pt)
CO6382113A2 (es) Compuestos quimicos
BR112015010570A2 (pt) agentes antimicrobianos
CY1116238T1 (el) Ενωσεις me αντιβακτηριακη δραστικοτητα εναντι clostridium
BR112019000988A2 (pt) derivado de triazolopirazinona útil como inibidor de pde1 humana
RS54689B1 (en) CONNECTED BICYCLIC 2,4- DIAMINOPYRIMIDINE DERIVATIVE AS DUAL ALK AND FAK INHIBITOR
BR112015026516A2 (pt) agentes antibacterianos de fenicol inovadores
BR112015030589A8 (pt) formas polimórficas de fosfato de icotinibe, composição farmacêutica compreendendo as referidas formas e usos das mesmas
WO2014101294A9 (zh) 糖肽类化合物或其药用盐及其制备方法、以及药物组合物和用途

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements